Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Audiology
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Orthopedics
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 2644

Mouse Model for Generation of Antibodies and Vaccine Antigens

Inventors: Frederick Alt, Hwei-Ling Cheng, Ming Tian

Invention Types: Therapeutics, Research Tool

Research Areas: Immunology

Keywords: Antibody, Vaccine, Mouse Model, Platform

For More Information Contact:  Dietz, Ryan

 

Invention Description:

Improved methods of producing variants of existing antibodies with higher affinities or modified specificities are important for clinical applications. Researchers at Boston Children’s Hospital have developed an antibody development platform utilizing a mouse model with a novel engineered immune system for the development of such antibody variants. The system allows rapid and efficient expression of any desired combination human variable region (VH, D, J, DJ, or VL) gene segments in mice to derive novel variant antibodies with improved affinity and/or specificity of known human antibodies including therapeutically useful antibodies.

Applications:

• Method to improve affinity and/or specificity of any therapeutic antibody for clinical application.

• Method to evaluate the efficacy of vaccine candidates and immunization protocols on affinity maturation, such as protection from HIV infection by Broadly Neutralizing Antibodies (BnAbs).

Competitive Advantages:

• In less than 9 months, researchers can generate a cohort of mice for immunization that express any desired human variable region exons in a large fraction of peripheral B cells.

• Model should be applicable for improving affinity/specificity of many antibodies generated by current immunization and phage display methods.

• Relatively inexpensive model to test vaccine approaches for the development of unusual (e.g. highly mutated) antibody responses (e.g. certain HIV broadly neutralizing antibodies).

Business Opportunity:

• Platform for sponsored research

• Startup or license opportunity

IPStatus: Pat. Pend.